Paris, France, April 7, 2026
Global Contracts Strengthen Aesthetic Market Leadership
In a major development for the global aesthetic and regenerative medicine market, CGBIO has announced the successful securing of $38 million in international supply agreements during its participation at the IMCAS World Congress 2025, the world’s largest aesthetic and plastic surgery conference. The event, held in Paris, brought together over 20,000 medical professionals from 136 countries, providing a powerful platform for industry leaders to showcase innovation and expand global partnerships.
CGBIO leveraged its exclusive exhibition booth to highlight its advanced portfolio of dermal fillers and PDO sutures, resulting in multiple high-value agreements across Europe, Latin America, and the Middle East. Among the key deals, the company signed a three-year $11.4 million exclusive supply agreement with a leading Brazilian pharmaceutical company for its LUXX polydioxanone (PDO) sutures, along with additional $3 million in confirmed on-site orders from Latin American markets. These achievements underscore CGBIO’s growing position as a global leader in aesthetic medical devices and regenerative solutions.
Advanced Product Portfolio Drives Commercial Success
CGBIO’s strong performance at IMCAS 2025 was driven by its innovative lineup of aesthetic and regenerative products, including Facetem, AiLEENE, and GISELLELIGNE dermal fillers, as well as its LUXX PDO suture technology. These products are designed to support non-surgical facial rejuvenation, tissue regeneration, and aesthetic enhancement, aligning with the rapidly growing demand for minimally invasive cosmetic procedures.
Advertisement
The company secured an additional $9.1 million three-year agreement to supply fillers across Greece, Iraq, and Israel, alongside $13.2 million in contracts spanning 18 countries, including Spain, the UK, Italy, Portugal, and Saudi Arabia. This widespread adoption reflects the increasing global demand for high-quality, clinically effective aesthetic solutions, particularly those based on calcium hydroxyapatite (CaHa) and hyaluronic acid (HA) technologies. By combining scientific innovation with commercial execution, CGBIO continues to expand its footprint in the highly competitive aesthetic medicine sector.
Clinical Education and Expert Engagement Enhance Adoption
Beyond commercial success, CGBIO reinforced its global presence through extensive clinical education initiatives, engaging healthcare professionals with advanced training programs and expert-led sessions. At IMCAS 2025, leading clinicians presented cutting-edge regenerative treatment techniques, including full-body applications of CaHa-based therapies and non-surgical facial rejuvenation methods using hyaluronic acid fillers.
These sessions demonstrated the clinical versatility and effectiveness of CGBIO’s products, while also fostering stronger relationships with the global medical community. Programs such as “Meet the Master” enabled knowledge exchange on advanced aesthetic procedures, including combination therapies using fillers and PDO sutures for enhanced lifting and contouring outcomes. This focus on education and clinical validation plays a critical role in accelerating product adoption and establishing long-term trust among practitioners, further strengthening CGBIO’s market position.
Strategic Expansion Across Global Markets
CGBIO’s achievements at IMCAS 2025 reflect a broader strategy to expand its presence across high-growth international markets, particularly in Europe, the Middle East, Latin America, and the CIS region. The company plans to further strengthen its global distribution network, while continuing to invest in research and development to deliver next-generation solutions in aesthetic and regenerative medicine.
With increasing demand for non-invasive cosmetic procedures and regenerative therapies, CGBIO is well-positioned to capitalize on evolving market trends and drive sustainable growth. The company’s ability to secure large-scale contracts and engage with global experts highlights its commitment to innovation, quality, and strategic market expansion, positioning it as a key player shaping the future of aesthetic MedTech solutions worldwide.
Source: CGBIO press release
